Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
PMGC Holdings Inc.
NorthStrive Acquisition Corp I has confirmed the forfeiture of 629,998 initial shares held by initial shareholders following the expiration of the unexercised over-allotment option. This action adjusts the total holdings of the initial shareholders to 4,200,000 shares to comply with the ownership percentage requirements stipulated in the underwriting agreement.…more
PMGC Holdings Inc.
PMGC Holdings Inc., as the sole member of NorthStrive Sponsor I LLC, amended and restated the company's operating agreement on September 25, 2026. Through this agreement, PMGC Holdings solidified its control over the 2,728,070 Class A ordinary shares of NorthStrive Acquisition Corp I. held by the entity and redefined the management and operational authority.…more
PMGC Holdings Inc.
PMGC Holdings has entered into a payment agreement with Longevity Health Holdings to secure royalty payments from the January 2025 sale of its Elevai Skincare business. Under the terms, the company will receive scheduled monthly cash payments of at least $10,000, including a $94,937 balance for 2025, through August 2031. This agreement provides non-dilutive, recurring cash flow to support the company's growth strategy.…more
29 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
PMGC Holdings Announces Rebranding to NorthStrive
PMGC Holdings has entered into a trademark license agreement to adopt the NorthStrive brand and plans to formally change its legal name within six months. This rebranding initiative aims to unify the company's corporate identity but does not carry immediate financial impact.…more
●●●●●●●● ●●●●● ●●●●●●
PMGC Holdings announced it is the sponsor of the $100 million SPAC NorthStrive Acquisition Corp I, holding a 21.4% stake. This disclosure of ownership structure does not provide immediate material impact on the company's stock price.…more
●●●●●●●● ●●●●● ●●●●●●
NorthStrive Biosciences has entered into an agreement with Charles River Laboratories to conduct analytical characterization for its EL-22 and EL-32 engineered probiotic candidates. This collaboration focuses on strengthening manufacturing and quality control frameworks as the programs move toward IND-enabling development.…more
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.